深化国际创新合作 共拓产业新局｜芝加哥大学Polsky创新中心到访蓝鹊生物
芝加哥大学Polsky创业与创新中心核心团队到访上海蓝鹊生物，双方围绕跨境生物医药创新、技术转化、产业合作以及生态建设深入对接，共同探索国际化产学研协同创新新模式。
Learn more
聚焦全球产能共建 助力卫生公平｜WHO董继萃博士一行到访蓝鹊生物交流调研
世界卫生组织（WHO）产品政策、可及性与生产支持单位（PAM）负责人董继萃博士一行莅临上海蓝鹊生物开展专项调研交流，聚焦WHO全球疫苗本地化生产、技术转移与健康公平发展目标。
Learn more
蓝鹊生物冻干带状疱疹mRNA疫苗（RQ3400）获国家药监局临床试验默示许可
蓝鹊生物与复旦大学、沃森生物合作开发的首款采用先进冻干制剂技术的冻干带状疱疹mRNA疫苗（RQ3400）获国家药监局临床试验默示许可，突破传统mRNA疫苗超低温储存瓶颈。
Learn more
蓝鹊生物RSV mRNA疫苗（RQ3201）获CDE临床试验默示许可 实现中美双报
继美国FDA IND获批之后，蓝鹊生物RSV mRNA疫苗（RQ3201）再获国家药品监督管理局药品审评中心（CDE）临床试验默示许可，成功实现「中美双报」战略目标。
Learn more
蓝鹊生物联合多家机构在《Vaccine》发表发热伴血小板减少综合征mRNA疫苗研究成果
蓝鹊生物与中国科学院武汉病毒研究所、复旦大学中山医院等合作，在国际疫苗学权威期刊《Vaccine》发表SFTSV mRNA疫苗研究成果，仅需1μg极低免疫剂量即可在动物模型中提供100%完全保护。
Learn more
面向全球健康的高可及性mRNA递送平台的研发｜盖茨基金会莅临蓝鹊生物开展专项交流
盖茨基金会代表团莅临上海蓝鹊生物开展专项技术交流，聚焦高可及性mRNA递送技术与全球传染病防控需求，围绕新型递送系统创新、传染病疫苗研发及产业化普惠应用开展深度对接。
Learn more
蓝鹊生物RSV mRNA疫苗（RQ3201）获美国FDA临床试验许可
蓝鹊自主研发的呼吸道合胞病毒（RSV）mRNA疫苗（RQ3201）成功获得美国食品药品监督管理局（FDA）临床试验申请（IND）许可，标志着公司mRNA技术平台获得国际权威监管认可。
Learn more
蓝鹊生物个性化肿瘤mRNA疫苗（RQ2500）获伦理批件 将开展临床研究
蓝鹊生物研发的个性化肿瘤mRNA疫苗（RQ2500），已分别获得复旦大学附属肿瘤医院和中国医学科学院肿瘤医院的伦理批件，将针对泛癌种适应症进行临床研究。
Learn more
人工智能驱动的可电离脂质理性设计用于mRNA递送
蓝鹊生物联合复旦大学、澳门大学在Nature Communications杂志发表研究文章，利用AI和虚拟筛选得到能够高效递送mRNA的脂质体新分子，评估了近2000万个可电离脂质体，最终得到一个脂质体分子的功效与脂质SM-102相似。
Learn more
CORE DOMAINS
Core Domains
We scale mRNA impact through three platform-enabled domains: infectious disease vaccine engineering, therapeutic immunology interventions, and durable therapeutic products for long-term dosing—forming a sustainable system from R&D to translation.
Prophylactic Vaccines
Prophylactic Vaccines
Built on a high-standard CMC quality system, overcoming process scale-up challenges to ensure batch-to-batch consistency and clinical safety at industrial production scale. Committed to rapid-response platform development and strategic stockpiling against highly pathogenic agents and zoonotic diseases.
Learn more →
Immuno-Oncology
Immuno-Oncology
Precisely define the clinical therapeutic window to maximize efficacy while effectively mitigating systemic risks such as cytokine release syndrome. Focused on therapeutic vaccines, tumor neoantigen vaccines, and in vivo in situ CAR-T / TCR-T cell reprogramming technologies.
Learn more →
Protein Replacement
Protein Replacement & Regeneration
Systematically optimize drug PK/PD profiles and in vivo biodistribution, addressing immunogenicity and tolerability challenges under long-term dosing. Focused on protein replacement, metabolic diseases, and rare disease areas to establish a sustainable R&D pathway with clinical advantages.
Learn more →
CAREERS
Careers
Transforming public health and tackling major diseases requires more than a single successful program—it takes an mRNA platform that can respond rapidly, manufacture reliably, and iterate continuously. That is why we are building long-term foundational capabilities with talent across molecular biology, delivery and materials, process development and QC, and clinical translation.
Join us to help make mRNA a global health infrastructure—accessible, scalable, and affordable for more people.
